BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18328272)

  • 1. Molecular diversity in the context of leadlikeness: compound properties that enable effective biochemical screening.
    Rishton GM
    Curr Opin Chem Biol; 2008 Jun; 12(3):340-51. PubMed ID: 18328272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pursuing the leadlikeness concept in pharmaceutical research.
    Hann MM; Oprea TI
    Curr Opin Chem Biol; 2004 Jun; 8(3):255-63. PubMed ID: 15183323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fragment-based activity space: smaller is better.
    Hesterkamp T; Whittaker M
    Curr Opin Chem Biol; 2008 Jun; 12(3):260-8. PubMed ID: 18316043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ChemGPS-NP: tuned for navigation in biologically relevant chemical space.
    Larsson J; Gottfries J; Muresan S; Backlund A
    J Nat Prod; 2007 May; 70(5):789-94. PubMed ID: 17439280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonleadlikeness and leadlikeness in biochemical screening.
    Rishton GM
    Drug Discov Today; 2003 Jan; 8(2):86-96. PubMed ID: 12565011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based pharmacophore screening for natural-product-derived PPARgamma agonists.
    Tanrikulu Y; Rau O; Schwarz O; Proschak E; Siems K; Müller-Kuhrt L; Schubert-Zsilavecz M; Schneider G
    Chembiochem; 2009 Jan; 10(1):75-8. PubMed ID: 19067454
    [No Abstract]   [Full Text] [Related]  

  • 7. A review of high throughput technology for the screening of natural products.
    Mishra KP; Ganju L; Sairam M; Banerjee PK; Sawhney RC
    Biomed Pharmacother; 2008 Feb; 62(2):94-8. PubMed ID: 17692498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Observations on screening-based research and some concerning trends in the literature.
    Baell JB
    Future Med Chem; 2010 Oct; 2(10):1529-46. PubMed ID: 21426147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plant natural products: back to the future or into extinction?
    McChesney JD; Venkataraman SK; Henri JT
    Phytochemistry; 2007 Jul; 68(14):2015-22. PubMed ID: 17574638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [High content drug screening and its application].
    Zhang L; Du GH
    Yao Xue Xue Bao; 2005 Jun; 40(6):486-90. PubMed ID: 16144310
    [No Abstract]   [Full Text] [Related]  

  • 11. The impact of natural products upon modern drug discovery.
    Ganesan A
    Curr Opin Chem Biol; 2008 Jun; 12(3):306-17. PubMed ID: 18423384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragonomics: fragment-based drug discovery.
    Zartler ER; Shapiro MJ
    Curr Opin Chem Biol; 2005 Aug; 9(4):366-70. PubMed ID: 15925537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolution of microarrayed compound screening.
    Hoever M; Zbinden P
    Drug Discov Today; 2004 Apr; 9(8):358-65. PubMed ID: 15081963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High throughput solubility determination with application to selection of compounds for fragment screening.
    Colclough N; Hunter A; Kenny PW; Kittlety RS; Lobedan L; Tam KY; Timms MA
    Bioorg Med Chem; 2008 Jul; 16(13):6611-6. PubMed ID: 18502135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targets looking for drugs: a multistep computational protocol for the development of structure-based pharmacophores and their applications for hit discovery.
    Tintori C; Corradi V; Magnani M; Manetti F; Botta M
    J Chem Inf Model; 2008 Nov; 48(11):2166-79. PubMed ID: 18942779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-based high-content screening of small-molecule libraries.
    Korn K; Krausz E
    Curr Opin Chem Biol; 2007 Oct; 11(5):503-10. PubMed ID: 17931958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel method for generating structure-based pharmacophores using energetic analysis.
    Salam NK; Nuti R; Sherman W
    J Chem Inf Model; 2009 Oct; 49(10):2356-68. PubMed ID: 19761201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragments, network biology and designing multiple ligands.
    Morphy R; Rankovic Z
    Drug Discov Today; 2007 Feb; 12(3-4):156-60. PubMed ID: 17275736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico fragment screening by replica generation (FSRG) method for fragment-based drug design.
    Fukunishi Y; Mashimo T; Orita M; Ohno K; Nakamura H
    J Chem Inf Model; 2009 Apr; 49(4):925-33. PubMed ID: 19354203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leadlikeness and structural diversity of synthetic screening libraries.
    Verheij HJ
    Mol Divers; 2006 Aug; 10(3):377-88. PubMed ID: 17031539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.